C3H / He mice bearing SCC VII
tumors received
5-bromo-2'-deoxyuridine (
BrdU) continuously for 5 days via implanted mini-osmotic pumps to label all proliferating (P) cells. The mice then received one of six different
DNA-damaging agents with or without mild temperature
hyperthermia (40 degrees C, 30 min, MTH). These agents were
adriamycin (ADM),
mitomycin C (MMC),
cyclophosphamide (CPA),
bleomycin (BLM),
cisplatin (CDDP), and
tirapazamine (TPZ). After the drug treatment, the
tumor-bearing mice were irradiated with a series of doses of gamma-rays. Immediately after irradiation, the
tumors were excised, minced and trypsinized. The
tumor cell
suspensions thus obtained were incubated with
cytochalasin-B (a cytokinesis blocker), and the micronucleus (MN) frequency in cells without
BrdU labeling ( = quiescent (Q) cells) was determined using immunofluorescence staining for
BrdU. The MN frequency in the total (P + Q)
tumor cells was determined from the
tumors that had not been pretreated with
BrdU. MTH significantly increased the MN frequency of total cells in
tumors irradiated with gamma-rays combined with CPA, BLM, CDDP or TPZ, and that of Q cells in
tumors irradiated with gamma-rays combined with BLM or TPZ. The sensitivity difference in the MN frequency between total and Q
tumor cells was significantly decreased by the combination with TPZ. TPZ combined with
radiotherapy and TPZ combined with thermo-
radiotherapy at mild temperatures appear to be promising modalities for sensitizing
tumor cells in vivo, including Q
tumor cells.